Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Danielle Bayer

Interventional Cardiology Lexington, KY Medical Doctor

NPI 1003202243 CMS profile 11302868

1720 Nicholasville Rd Ste 400, Lexington, KY 40503

Open in the dashboard

General payments

$9,520

140 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danielle Bayer of Lexington, KY is reported in the CMS Open Payments database as having received $9,520 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,073 28
2024 General $1,102 25
2023 General $1,320 43
2022 General $3,515 41
2021 General $509 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Bayer
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Danielle Bayer were reported at $3,073. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Danielle Bayer Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $509 $677 $233–$1,827 $132
2022 $3,515 $978 $333–$2,724 $149
2023 $1,320 $1,136 $382–$2,986 $160
2024 $1,102 $1,181 $395–$3,326 $164
2025 $3,073 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $4,256 87 payments
  2. Edwards Lifesciences Corporation $2,007 19 payments
  3. Boston Scientific Corporation $1,058 10 payments
  4. AOP Health US, LLC $767 2 payments
  5. Medtronic, Inc. $755 8 payments
  6. Abiomed $415 5 payments
  7. Shockwave Medical, Inc $106 1 payment
  8. Amgen Inc. $34 2 payments
  9. Biosense Webster, Inc. $32 1 payment
  10. Novartis Pharmaceuticals Corporation $21 1 payment
  11. Other $69 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,723 126 payments
  2. Travel and Lodging $2,495 12 payments
  3. Grant $302 2 payments
Products named General payments · program years 2021–2025
  1. TRICLIP $1,516 9 payments
  2. MITRACLIP Structural Heart $1,346 15 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,203 10 payments
  4. Rapiblyk Cardiovascular $767 2 payments
  5. Rapiblyk Cardiovascular $767 2 payments
  6. COREVALVE EVOLUT R $731 7 payments
  7. MITRACLIP Vascular $416 25 payments
  8. Impella $395 4 payments
  9. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $293 4 payments
  10. WATCHMAN FLX $262 4 payments
  11. Other $1,866 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,302

Median for Cardiology: 2,533

Drug cost

$216,549

Median for Cardiology: $485,213

Branded share of claims

23.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 111 $117,824
Entresto Sacubitril/Valsartan Brand 23 $30,581
Jardiance Empagliflozin Brand 26 $23,672
Farxiga Dapagliflozin Propanediol Brand 16 $20,119
Xarelto Rivaroxaban Brand 12 $8,746
Atorvastatin Calcium Generic 192 $3,199
Metoprolol Succinate Generic 133 $1,856
Ezetimibe Generic 35 $1,558
Clopidogrel Clopidogrel Bisulfate Brand 99 $1,435
Amiodarone Hcl Generic 50 $1,179

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$109,729

Of which drugs: $450

Medicare patients

353

Average age 76

Services billed

1,208

188 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Heart failure 50%
Arthritis 50%
Atrial fibrillation 45%
Diabetes 41%
Chronic kidney disease 40%
COPD 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 15 60 $407

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record